Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in revenue from its weight loss and obesity drugs Mounjaro and ...

CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results. Registered dietician Abbey Sharp explains the best and worst foods to eat after the expiration date ...

(Reuters) -Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Eli Lilly (NYSE: LLY) has become a beast in healthcare ... which weren't great either. For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates ...

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Eli Lilly and Ozempic and Wegovy-maker Novo Nordisk (NVO) are testing their weight-loss drugs' abilities to treat conditions that typically accompany obesity, such as diabetes and sleep apnea.

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 36.07% higher than today’s price of $756.99.

The Great British Bake Off host Alison Hammond is living her happiest, healthiest life after an astonishing 150-lb weight loss. And she did it without turning to surgery or weight loss drugs like ...

Trump did not retract his threat of economic coercion during the 45-minute phone conversation ... Eli Lilly (NYSE:LLY), makes the main active ingredient in its popular obesity and diabetes ...